- Home
- IPHA vs FLC Comparison
IPHA vs FLC Comparison
Compare IPHA & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- FLC
- Stock Information
- Founded
- IPHA 1999
- FLC 2003
- Country
- IPHA France
- FLC United States
- Employees
- IPHA N/A
- FLC N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- FLC Trusts Except Educational Religious and Charitable
- Sector
- IPHA Health Care
- FLC Finance
- Exchange
- IPHA Nasdaq
- FLC Nasdaq
- Market Cap
- IPHA 160.1M
- FLC 174.2M
- IPO Year
- IPHA 2019
- FLC N/A
- Fundamental
- Price
- IPHA $1.74
- FLC $17.17
- Analyst Decision
- IPHA Strong Buy
- FLC
- Analyst Count
- IPHA 1
- FLC 0
- Target Price
- IPHA $11.00
- FLC N/A
- AVG Volume (30 Days)
- IPHA 11.2K
- FLC 37.8K
- Earning Date
- IPHA 09-11-2025
- FLC 01-01-0001
- Dividend Yield
- IPHA N/A
- FLC 6.64%
- EPS Growth
- IPHA N/A
- FLC N/A
- EPS
- IPHA N/A
- FLC N/A
- Revenue
- IPHA $20,831,349.00
- FLC N/A
- Revenue This Year
- IPHA $209.83
- FLC N/A
- Revenue Next Year
- IPHA $83.15
- FLC N/A
- P/E Ratio
- IPHA N/A
- FLC N/A
- Revenue Growth
- IPHA N/A
- FLC N/A
- 52 Week Low
- IPHA $1.29
- FLC $12.62
- 52 Week High
- IPHA $3.51
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- IPHA 42.70
- FLC 68.17
- Support Level
- IPHA $1.71
- FLC $16.86
- Resistance Level
- IPHA $1.90
- FLC $17.12
- Average True Range (ATR)
- IPHA 0.08
- FLC 0.12
- MACD
- IPHA 0.00
- FLC 0.01
- Stochastic Oscillator
- IPHA 47.62
- FLC 100.00
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.